Table 2:

Results of meta-analysisa

OverallDEDSPEDIntergroup Heterogeneity
Efficacy outcomes
 Technical success99.6% (98.6%–99.8%)
I2 = 33.0% P = .165
100% (99.2%–100%)
I2 = 0.00% P = .487
99.2% (97.2%–100%)
I2 = 54.4% P = .087
P = .165
 Aneurysm occlusion rate (6 mo)80.5%b (74.5%–86.0%)
I2 = 70.8% P = .000
78.9% (74.3%–83.1%)
I2 = 0.00% P = .559
82.7%b (73.4%–90.4%)
I2 = 75.3% P = .000
P = .420
 Aneurysm occlusion rate (12 mo)85.6% (80.6%–90.0%)
I2 = 0.00% P = .744
87.8% (80.9%–93.5%)
NA
83.2% (75.8%–89.6%)
NA
P = .329
Safety outcomes
 Mortality rate1.0% (0.3%–1.9%)
I2 = 0.00% P = .608
1.3% (0.2%–3.1%)
I2 = 5.47% P = .366
0.8% (0.1%–1.9%)
I2 = 0.00% P = .675
P = .410
 Morbidity rate6.0% (4.5%–7.7%)
I2 = 0.00% P = .857
6.3% (3.9%–9.1%)
I2 = 0.00% P = .618
5.8% (3.9%–8.1%)
I2 = 0.00% P = .710
P = .725
 Total ischemia rate6.7%b (4.1%–10.1%)
I2 = 61.9% P = .010
8.3%b (2.9%–15.7%)
I2 = 75.1% P = .007
6.3% (3.2%–10.2%)
I2 = 50.1% P = .111
P = .548
 Serious ischemia rate1.8% (0.8%–3.0%)
I2 = 12.1% P = .335
2.5% (1.0%–4.6%)
I2 = 0.00% P = .685
1.2% (0.1%–3.2%)
I2 = 37.0% P = .190
P = .240
  • Note:—NA indicates not applicable.

  • a Table shows pooled point estimate, 95% confidence intervals, heterogeneity (I2 statistic and P value for the Cochrane Q test) and intergroup heterogeneity for all outcomes of the meta-analysis.

  • b Significant heterogeneity.